Table 1.
Simulated range of exposure (AUC0–336 h) and number of patients for weight‐based (10 mg/kg) and flat (800 mg) dosing of avelumab by quartiles of baseline body weight using the first‐cycle population pharmacokinetic model
| Weight quartiles | N | Median AUC0–336 h, mg/L*h (range) | |
|---|---|---|---|
| 10 mg/kg | 800 mg | ||
| Q1 (30.4 to ≤ 60.0 kg) | 415 | 19,102 (8,271–36,965) | 29,418 (14,191–54,763) |
| Q2 (60.0 to ≤ 70.6 kg) | 404 | 22,221 (9,057–35,556) | 27,170 (10,893–45,739) |
| Q3 (70.6 to ≤ 84.6 kg) | 435 | 24,720 (12,970–51,742) | 25,280 (13,627–51,103) |
| Q4 (84.4 to ≤ 204 kg) | 409 | 27,681 (7,438–44,938) | 22,583 (5,689–38,309) |
| Overall | 1,663 | 23,160 (7,438–51,742) | 25,913 (5,689–54,763) |
AUC0–336 h, area under the curve during the first dosing interval.